CLINICAL EXPERIENCE IN USING COMBINED FERROTHERAPY WITH L-CARNITINE IN STANDARD TREATMENT OF PATIENTS WITH CHRONIC HEART FAILURE WITH REDUCED LEFT VENTRICLE EJECTION FRACTION WITH CONCOMITANT IRON DEFICIENCY ANEMIA

Valeriy P Ivanov; Mariіa O Kolesnyk; Oleg N Kolesnуk

doi:10.31435/rsglobal_ws/31102019/6718

Valeriy P Ivanov Professor, Head of internal medicine department №3, Ukraine, Vinnytsya, National Pirogov Memorial Medical University, Vinnytsya
Mariіa O Kolesnyk Assistant professor, Department of internal medicine №3, Ukraine, Vinnytsya, National Pirogov Memorial Medical University, Vinnytsya
Oleg N Kolesnуk Associate professor, Department of internal medicine №3, Ukraine, Vinnytsya, National Pirogov Memorial Medical University, Vinnytsya

DOI: https://doi.org/10.31435/rsglobal_ws/31102019/6718

Keywords: сhronic heart failure, iron deficiency, iron deficiency anemia, oral ferrotherapy, L-carnitine

Abstract

Chronic heart failure (CHF) is a global public health problem. Despite all the technical advances available in modern cardiology, a medical strategy for the treatment of CHF has been and remains the main focus of therapeutic intervention. А particular problem is the treatment of CHF with concomitant pathology. The modern pharmacological strategy for the treatment of patients with CHF and iron deficiency anemia, except iron preparations, must take into account the use of agents that have antihypoxic, antioxidant and membrane-stabilizing effects, and at the same time regulatory effect on the metabolism of physiologically active compounds to improve the condition of patients. Therefore, this study is aimed to evaluate the effectiveness of iron deficiency anemia’s correction, identify and compare the effect of oral ferrotherapy and combined use of ferrotherapy with L-carnitine on clinical and instrumental parameters of patients with chronic heart failure with reduced ejection fraction of left ventricle as possible variants of additional therapy to standard treatment.

References

Moayedi Y, Kobulnik J. Chronic heart failure with reduced ejection fraction. CMAJ. 2015 Apr 21; 187(7): 518.

Felker GM, Adams KF Jr, Gattis WA, O'Connor CM. Anemia as a risk factor and therapeutic target in heart failure. J Am Coll Cardiol. 2004; 44:959.

Iванов ВП, Koлесник MO, Koлесник OM, Iванов ЄI. Анемії в ракурсі проблеми хронічної серцевої недостатності: патогенез і лабораторна діагностика. Львівський медичний часопис. 2018; 2 (24), 69-76.

Стуклов НИ. Дефицит железа и анемия у болных хронической сердечной недостаточностю. Рац. фармакотерапия в кардиологии. 2017; 3 (5), 651– 660.

Anand, I.S., Gupta, P. (2018) Anemia and Iron Deficiency in Heart Failure Current Concepts and Emerging Therapies. Circulation, 138, 80–98. doi: 10.1161/circulationaha.118.030099

Anand, I.S. (2008) Anemia and chronic heart failure implications and treatment options. J Am Coll Cardiol, 52, 501–511. doi: 10.1016/j.jacc.2008.04.044.

Іvanov VP, Kolesnyk MO. Сomparative characteristics of quality of life indicators in patients with chronic heart failure with reduced left ventricular ejection fraction depending on iron deficiency type. Eastern Ukrainian Medical Journal. 2019; 3 (7), 246-256.

Єрмак ОС, Кравчун ПГ, Риндіна НГ, Ринчак ПІ, Титова ГЮ. Терапевтична корекція анемії у хворих із хронічною серцевою недостатністю ішемічного генезу препаратами заліза в комбінації з кверцетином. Запорожский медицинский журнал. 2017; 5 (104): 570-576.

Haselhuhn LR, Brotman DJ, Wittstein IS. Heart failure guidelines: What you need to know about the 2017 focused update. Cleveland clinic journal of medicine. 2019; 2 (86): 123- 139. doi:10.3949/ccjm.86a.18022

Drozd M, Jankowska EA, Banasiak W, Ponikowski P. Iron therapy in patients with heart failure and iron deficiency: review of iron preparations for practitioners. Am J Cardiovasc Drugs. 2017; 17(3):183–201. doi:10.1007/s40256-016-0211-2

Воронков ЛГ. Анемия у пациента с ХСН: как оценивать и как лечить? Серцева недостатність. 2015; 2: 5-15